Use of favipiravir against Covid-19: A Review: Use of Favipiravir Against Covid-19: A Review

Eiman  Syed; Mati  Ullah; Ataul  Mustafa; Sana  Ashiq

doi:10.54393/pbmj.v5i2.202

Authors

Eiman Syed Department of Medical Laboratory Technology, Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Lahore, Pakistan.
Mati Ullah Government College University, Faisalabad
Ataul Mustafa Government College University, Faisalabad
Sana Ashiq Centre for Applied Molecular Biology, University of the Punjab, Lahore-Pakistan

DOI:

https://doi.org/10.54393/pbmj.v5i2.202

Keywords:

Covid-19, Favipiravir, Coronavirus, Pandemic

Abstract

Coronavirus disease 2019 (COVID-19) emerged as a global challenge for the world healthcare community. The use of favipiravir against COVID-19 was studied in various studies but its efficacy and side effects remain uncertain. Therefore, we aimed to analyze the use of favipiravir in patients suffering from coronavirus.The literature search was done by using several databases including MEDLINE, Google Scholar, Web of Science, PubMed, and Science Direct. To ensure the credibility and accuracy of the included articles we include only those studies that were published in indexed journals. Furthermore, in this current review, we mainly include only those studies published from January 2015 to September2021. We included all the review and research articles published in the English language.The review of currently available literature suggests the use of favipiravir showed both some utility and side effects in patients diagnosed with coronavirus-19. Moreover, the use of this antiviral drug may show a promising role in mild to moderate COVID-19 patients and it may reduce the need for prolonged hospital stay and mechanical ventilation. But there is still a need to confirm the side effects and favipiravir efficacy in the patients suffering from this fatal disease.

References

Khanna RC, Cicinelli MV, Gilbert SS, Honavar SG, Murthy GV. COVID-19 pandemic: Lessons learned and future directions. Indian J Ophthalmol. 2020;68(5):703.

https://doi.org/10.4103/ijo.IJO_843_20

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020;7(1):1-0.

https://doi.org/10.1186/s40779-020-00240-0

Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544-55.

https://doi.org/10.1016/j.tim.2013.05.005

Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3).

https://doi.org/10.7759/cureus.7423

Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678.

https://doi.org/10.7150/ijbs.45053

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes & Infect. 2020;9(1):221-36.

https://doi.org/10.1080/22221751.2020.1719902

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-2.

https://doi.org/10.1038/s41591-020-0820-9

Morawska L. Droplet fate in indoor environments, or can we prevent the spread of infection?. Indoor air. 2006;16(5):335-47.

https://doi.org/10.1111/j.1600-0668.2006.00432.x

Ashiq K, Ashiq S, Bajwa MA, Tanveer S, Qayyum M. Knowledge, attitude and practices among the inhabitants of Lahore, Pakistan towards the COVID-19 pandemic: an immediate online based cross-sectional survey while people are under the lockdown. Bangladesh J Medical Sci. 2020;19:S69-76.

https://doi.org/10.3329/bjms.v19i0.48169

Yuki K, Fujiogi M, KoutsogiannakiS. COVID-19 pathophysiology: A review. Clinical immunology (Orlando, Fla.). 2020;215:108427.

https://doi.org/10.1016/j.clim.2020.108427

Zeouk I, Bekhti K, Lorenzo-Morales J. From Wuhan to COVID-19 pandemic: An up-to-date review of its pathogenesis, potential therapeutics, and recent advances. Microorganisms. 2020;8(6):850.

https://doi.org/10.3390/microorganisms8060850

Hossain MF, Hasana S, Al Mamun A, Uddin MS, Wahed MI, Sarker S, et al. COVID-19 outbreak: pathogenesis, current therapies, and potentials for future management. Front Pharmacol. 2020;11.

https://doi.org/10.3389/fphar.2020.563478

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20.

https://doi.org/10.1128/JVI.00127-20

Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192.

https://doi.org/10.1007/s11684-020-0754-0

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020.

https://doi.org/10.1056/NEJMoa2001316

Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21(7):2657.

https://doi.org/10.3390/ijms21072657

Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020. 83(6), 521-523.

https://doi.org/10.1097/JCMA.0000000000000319

Ye Q, Wang B, Mao J. The pathogenesis and treatment of theCytokineStorm'in COVID-19. J Infect. 2020;80(6):607-13.

https://doi.org/10.1016/j.jinf.2020.03.037

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020;395(10229):1054-62.

https://doi.org/10.1016/S0140-6736(20)30566-3

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663-5.

https://doi.org/10.1056/NEJMc2005073

Yuan W, Liu S, Lu L, Feng J, He X. Clinical interventions for severe and critical COVID-19: what are the options. Am J Transl Res. 2020;12(5):2110.

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981-6.

https://doi.org/10.1128/AAC.49.3.981-986.2005

Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B. 2017;93(7):449-63.

https://doi.org/10.2183/pjab.93.027

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446-54.

https://doi.org/10.1016/j.antiviral.2013.09.015

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug DiscovTher. 2020;14(1):58-60.

https://doi.org/10.5582/ddt.2020.01012

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192-8.

https://doi.org/10.1016/j.eng.2020.03.007

Xuan Y. Initial clinical results announced for favipiravir treatment of novel coronavirus pneumonia-viral clearance in four days. Biodiscover. 2020.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.

https://doi.org/10.1038/s41422-020-0282-0

Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Zhang J, Yin P. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.

https://doi.org/10.1101/2020.03.17.20037432

Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KP, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.

https://doi.org/10.1016/j.antiviral.2020.104786

Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E, INMI Ebola Team. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.PLOS Negl Trop Dis. 2017;11(12), e0006034.

https://doi.org/10.1371/journal.pntd.0006034

Mishima E, Anzai N, Miyazaki M, Abe T. Uric acid elevation by favipiravir, an antiviral drug. Tohoku J Exp Med. 2020;251(2):87-90.

https://doi.org/10.1620/tjem.251.87

Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79-81.

https://doi.org/10.1017/dmp.2014.151

Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85-94.

https://doi.org/10.1016/j.antiviral.2018.03.003

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=COVID&term=favipiravir&cntry=&state=&city=&dist= Accessed 1st July 2020.

Fujifilm announces the start of a phase III clinical trial of influenza antiviral drug "Avigan Tablet" on COVID-19 and commits to increasing production. Fujifilm Global. (2020). https://www.fujifilm.com/news/n200331_02.html. (Assessed on 3/7/2020).

THE HINDU. Glenmark begins Phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 patients in India.https://www.thehindu.com/news/national/glenmark-begins-phase-3-clinical-trials-on-antiviral-drug-favipiravir-for-covid-19-patients-in-india/article31563198.ece.(Assessed on 2/7/2020).

Clinical study to evaluate the performance and safety of favipiravir in COVID-19 - Full Text View - ClinicalTrials.gov. Clinicaltrials.gov.

https://clinicaltrials.gov/ct2/show/NCT04336904?draw=4. (Assessed on 3/7/2020).

Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials.Sci Rep. 2021;11(1):1-1.

https://doi.org/10.1038/s41598-021-90551-6

Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1-3.

https://doi.org/10.1186/s12879-021-06164-x

Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FF, Abd El Ghafar MS, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949-54.

https://doi.org/10.1007/s00705-021-04956-9